Neutral
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Day One Biopharmaceuticals (NASDAQ:DAWN) to a "Hold" rating. The company has a consensus "Hold" rating with an average target...